Sign in

CIK 0001512762

  • Accelerated filer
  • Smaller reporting company

Coherus Oncology, Inc.

Sign in to watch
Ticker
CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
273615821
Phone
+1 650-649-3530
Business address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
Former names
Coherus BioSciences, Inc., BioGenerics, Inc.
  1. 4 Other disposition Director disposed of 983,221 shares (other)
  2. 4 Open-market sale Chief Operating Officer sold 5,000 shares at $19.37 ($96,851)
  3. 4 Derivatives Options or other derivatives
  4. 3 Insider Initial Statement of Ownership
  5. 4 Open-market sale Chief Operating Officer sold 15,000 shares at $18.25 ($273,687)
  6. 4 Exercise or conversion President & CEO acquired 29,994 shares (option exercise)
  7. 4 Open-market sale Director sold 54,997 shares at $17.58 ($966,759)
  8. 4 Open-market sale Chief Operating Officer sold 2,500 shares at $17.22 ($43,050)
  9. 4 Open-market sale Director sold 200,000 shares at $17.15 ($3,430,020)
  10. 4 Open-market sale Chief Financial Officer sold 1,278 shares at $17.66 ($22,569)
  11. 4 Open-market sale Chief Operating Officer sold 3,093 shares at $17.17 ($53,107)
  12. 4 Open-market sale Chief Operating Officer sold 10,150 shares at an average $16.30 ($165,400)
  13. 4 Open-market sale Director sold 118,066 shares at an average $20.12 ($2,375,409)
  14. 4 Open-market sale Chief Financial Officer sold 3,159 shares at $22.33 ($70,552)
  15. 4 Open-market sale Chief Operating Officer sold 10,000 shares at an average $21.64 ($216,390)
  16. 4 Open-market sale Chief Operating Officer sold 10,000 shares at an average $19.59 ($195,931)
  17. 4 Open-market sale Chief Financial Officer sold 6,318 shares at an average $19.85 ($125,424)
  18. 4 Derivatives Options or other derivatives
  19. 4 Derivatives Options or other derivatives
  20. 4 Derivatives Options or other derivatives

Page 9 of 20 · 399 filings